SBIR/STTR Research Award

Environmental DNA Natural Product Discovery Through An Engineered Host

Award identifier 27b2c9555efe408492f8d542436f57558a54d552634197386de6e8dcce3d42acAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$198,047

Program and phase

SBIR · Phase I

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
EarthGenes Pharmaceuticals
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The broad objective of the proposal is to test whether E. coli hosts genetically altered to support complex natural product biosynthesis improve the success of screening environmental DNA libraries for novel and useful antibiotics and consists of the following Specific Aims: (1) To further modify both the E. coli strains engineered to produce polyketides and non-ribosomal peptides, and our BAC vector in which libraries are constructed, to allow screening of large- insert environmental DNA BAC clones in both single and multiple copy number; (2) To construct an environmental library in the modified BAC vector and to screen for antibiotic activity from environmental DNA libraries, in both low and high copy, transferred to native and genetically modified E. coli hosts. In Specific Aim 1, both the E. coli strains currently used for complex natural product production and the vector system used for high-throughput environmental DNA antibiotic screening will be modified and made compatible for efforts to integrate these advanced E. coli heterologous hosts into environmental DNA screening schemes. Aim 2 will then test for advanced antibiotic screening success based upon use of advanced E. coli heterologous hosts. Success will point to a new level of accessibility to as- yet-undiscovered antibiotic agents. Success will provide new antibiotic compounds to be used in the continual battle against antibiotic-resistant bacteria. More broadly, a method will be developed to access more chemically diverse natural products (antibiotics, anticancer agents, immunosuppressants, or others) from previously inaccessible terrestrial and marine natural environments.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.